Shares of Myriad Genetics closed Friday down 4% after United Healthcare (UNH) added a Current Procedural Terminology code and simplified the coverage rationale on its existing medical policy for pharmacogenetics, Piper Jaffray analyst William Quirk tells investors in a research note. The updated policy does not include a review of the Genesight dossier/Guided study, says the analyst. He views the change at United Healthcare as “minor” and keeps an Overweight rating on Myriad Genetics. Quirk continues to look for positive Genesight coverage.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.